Extracellular ATP drives systemic inflammation, tissue damage and mortality

Cell Death and Disease

Volumn 5, Issue 3, 2014, Pages

  Cauwels, A ^a,b   Rogge, E ^a,b   Vandendriessche, B ^a,b   Shiva, S ^c   Brouckaert, P ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Apyrase; ATP; In vivo; LPS; Suramin

Indexed keywords

ADENOSINE TRIPHOSPHATE; APYRASE; INFLAMMASOME; INTERLEUKIN 10; INTERLEUKIN 1BETA; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; SURAMIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; MORBIDITY; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; APYRASE; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXINS; FEMALE; HYDROLYSIS; INFLAMMASOMES; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MITOCHONDRIA; PURINERGIC P2 RECEPTOR ANTAGONISTS; SIGNAL TRANSDUCTION; SURAMIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TIME FACTORS;

EID: 84897446326     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.70     Document Type: Article

References (34)

1. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306: 2614-2615
2. Harrois A, Huet O, Duranteau J. Alterations of mitochondrial function in sepsis and critical illness. Curr Opin Anaesthesiol 2009; 22: 143-149.
3. Hernandez G, Bruhn A, Ince C. Microcirculation in sepsis: new perspectives. Curr Vasc Pharmacol 2013; 11: 161-169.
4. Dominguez JA, Coopersmith CM. Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Crit Care Clin 2010; 26: 549-565.
5. Buchman TG, Cobb JP, Lapedes AS, Kepler TB. Complex systems analysis: a tool for shock research. Shock 2001; 16: 248-251.
6. Vandendriessche B, Peperstraete H, Rogge E, Cauwels P, Hoste E, Stiedl O et al. A Multiscale Entropy-based Tool for Scoring Severity of Systemic Inflammation. Crit Care Med 2014 (in press).
7. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. 2001SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
8. Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013; 381: 774-775.
9. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
10. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990; 49: 186-196.
11. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328: 1457-1460.
12. Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479: 117-121.
13. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222-230.
14. Fitz JG. Regulation of cellular ATP release. Trans Am Clin Climatol Assoc 2007; 118: 199-208.
15. Labasi JM, Petrushova N, Donovan C, McCurdy S, Lira P, Payette MM et al. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 2002; 168: 6436-6445.
16. Pelegrin P, Barroso-Gutierrez C, Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J Immunol 2008; 180: 7147-7157.
17. He Y, Franchi L, Nunez G. TLR. agonists stimulate Nlrp3-dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol 2013; 190: 334-339.
18. Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003; 64: 785-795.
19. Lecut C, Faccinetto C, Delierneux C, van Oerle R, Spronk HM, Evans RJ et al. ATP-gated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012; 10: 453-465.
20. Vanden Berghe T, Demon D, Bogaert P, Vandendriessche B, Goethals A, Depuydt B et al. Simultaneous targeting of Interleukin-1 and -18 is required for protection against inflammatory and septic shock. Am J Resp Crit Care Med 2014; 189: 282-291.
21. Schroder K, Tschopp J. The Inflammasomes. Cell 2010; 140: 821-832.
22. Duprez L, Takahashi N, Van Hauwermeiren F, Vandendriessche B, Goossens V, Vanden Berghe T et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 2011; 35: 908-918.
23. Lamkanfi M, Walle LV, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev 2011; 243: 163-173.
24. Gitter AH, Bendfeldt K, Schulzke JD, Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. Faseb J 2000; 14: 1749-1753.
25. Piguet PF, Vesin C, Donati Y, Barazzone C. TNF-induced enterocyte apoptosis and detachment in mice: Induction of caspases and prevention by a caspase inhibitor, ZVAD-fmk. Lab Invest 1999; 79: 495-500.
26. Wu ZQ, Han XD, Wang Y, Yuan KL, Jin ZM, Di JZ et al. Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 2011; 68: 87-96.
27. Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol 2003; 18: 479-497.
28. Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011; 108: 4659-4665.
29. Williams M, Jarvis MF. Purinergic and pyrimidinergic receptors as potential drug targets. Biochem Pharmacol 2000; 59: 1173-1185.
30. Hohenegger M, Matyash M, Poussu K, Herrmann-Frank A, Sarkozi S, Lehmann-Horn F et al. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs. Mol Pharmacol 1996; 50: 1443-1453.
31. Zhang YL, Keng YF, Zhao Y, Wu L, Zhang ZY. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatases. J Biol Chem 1998; 273: 12281-12287.
32. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003; 4: 387-393.
33. Bultinck J, Brouckaert P, Cauwels A. The in vivo contribution of hematopoietic cells to systemic TNF and IL-6 production during endotoxemia. Cytokine 2006; 36: 160-166.
34. Landegren U. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 1984; 67: 379-388.